SCHEMBL22044488

SCHEMBL22044488

Oc1ccc(F)cc1-c1nncnn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.56
IDO1 P14902 3/20 0.47
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
PLAT P00750 1/20 0.38
PRSS1 P07477 1/20 0.38
CHEK2 O96017 3/20 0.37
CHEK1 O14757 2/20 0.36
KDM1A O60341 5/20 0.36
HDAC6 Q9UBN7 4/20 0.35
HDAC1 Q13547 3/20 0.35
CASP6 P55212 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22043778 0.77 HSD11B1 (0.38) NPC1IDO1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL22044487 0.77 NPC1 (0.33) NPC1
SCHEMBL24022842 0.77 NISCH (0.44) CYP1A2CYP3A4CYP2D6MAPK1CYP2C19
SCHEMBL24334049 0.77 NPC1 (0.33) NPC1
SCHEMBL27520217 0.77 IDO1 (0.57) NPC1IDO1MAPTRAB9ASMN1; SMN2
SCHEMBL8059885 0.76 IDO1 (0.57) NPC1IDO1CA3CA6CA5A
SCHEMBL21994273 0.73 S1PR1 (0.42) NPC1KDM1AHDAC6HDAC1MAPT
SCHEMBL17866357 0.72 NPC1 (1.00) NPC1IDO1F2F10PLG
SCHEMBL24333878 0.71 ALOX5AP (0.40) HDAC1
SCHEMBL22044253 0.69 KDM4E (0.49) MAPTCYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119359-A1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING Københavns Universitet (DK) 2022-04-21 US disclosed
WO-2020108720-A1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING Københavns Universitet (DK) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119359-A1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING RTN3, RXFP3, TAAR5 NPC1 867/4885IDO1 912/4885CA3 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.